Head-to-head evidence
Aflibercept vs Tarcocimab tedromer
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
Aflibercept · Eylea
Marketed by Regeneron Pharmaceuticals and partners
NCT00509795 · Phase 3 · completed
The trial randomly assigned 1,217 participants and used quadruple blinding with ranibizumab as an active comparator. Its hard clinical primary endpoint—maintaining vision at week 52—met the prespecified non-inferiority criterion for all three aflibercept regimens, supporting a strong evidence grade.
Next expected readout: December 2026 · NCT06856577 (registry estimate)
Tarcocimab tedromer
Developed by Kodiak Sciences Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aflibercept's landscape · Tarcocimab tedromer's landscape